Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents

Objectives: The current study was aimed at examining SARS-CoV-2 immune responses following two doses of Comirnaty (R) COVID-19 vaccine among elderly people in nursing homes. Methods: A prospective cohort study in a representative sample from nursing homes in Valencia (n = 881; males: 271, females 61...

Descripción completa

Detalles Bibliográficos
Autores: Albert E, Burgos JS, Peiró S, Salas D, Vanaclocha H, Giménez E, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Navarro D
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p11347
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/11347
Access Level:acceso abierto
Palabra clave:Comirnaty (R) COVID-19 vaccine
Nursing home residents
SARS-CoV-2
SARS-CoV-2-S antibodies
id ES_07ba2c35dc8fd61d8b3fd54522c392bc
oai_identifier_str oai:fisabio.fundanetsuite.com:p11347
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residentsAlbert EBurgos JSPeiró SSalas DVanaclocha HGiménez ELimón RAlcaraz MJSánchez-Payá JDíez-Domingo JNavarro DComirnaty (R) COVID-19 vaccineNursing home residentsSARS-CoV-2SARS-CoV-2-S antibodiesObjectives: The current study was aimed at examining SARS-CoV-2 immune responses following two doses of Comirnaty (R) COVID-19 vaccine among elderly people in nursing homes. Methods: A prospective cohort study in a representative sample from nursing homes in Valencia (n = 881; males: 271, females 610; median age, 86 years) recruited residents using a random one-stage cluster sampling approach. A lateral flow immunochromatography device (LFIC) (OnSite COVID-19 IgG/IgM Rapid Test; CTK BIOTECH, Poway, CA, USA) was used as the front-line test for detecting SARS-CoV-2-Spike (S)-specific antibodies in whole blood obtained using a fingerstick. Residents returning negative LFIC results underwent venipuncture and testing for presence of SARS-CoV-2-S-reactive antibodies and T cells using the Roche Elecsys (R) Anti-SARS-CoV-2 S (Roche Diagnostics, Pleasanton, CA, USA), the LIAISON (R) SARS-CoV-2 TrimericS IgG assay (Diasorin S.p.A, Saluggia, Italy) and by flow cytometry, respectively. Results: The SARS-CoV-2-S antibody detection rate in nursing home residents was 99.6% (283/284) and 98.3% (587/597) for SARS-CoV-2 recovered and naive residents, respectively, within a median of 99 days (range 17-125 days) after full vaccination. Three out of five residents lacking SARS-CoV-2-S antibodies had detectable S-reactive CD8(+) and/or CD4(+) T cells. In addition, 50/50 and 40/50 participants with detectable SARS-CoV-2 antibodies also had SARS-CoV-2-S reactive interferon-gamma-producing CD4(+) and CD8(+) T cells, respectively. Discussion: The Comirnaty (R) COVID-19 vaccine is highly immunogenic in nursing home residents. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.ELSEVIER SCI LTD2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/11347CLINICAL MICROBIOLOGY AND INFECTIONISSN: 1198743XISSNe: 14690691reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p113472026-06-11T12:45:17Z
dc.title.none.fl_str_mv Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
title Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
spellingShingle Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
Albert E
Comirnaty (R) COVID-19 vaccine
Nursing home residents
SARS-CoV-2
SARS-CoV-2-S antibodies
title_short Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
title_full Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
title_fullStr Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
title_full_unstemmed Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
title_sort Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty (R) COVID-19 vaccine in nursing home residents
dc.creator.none.fl_str_mv Albert E
Burgos JS
Peiró S
Salas D
Vanaclocha H
Giménez E
Limón R
Alcaraz MJ
Sánchez-Payá J
Díez-Domingo J
Navarro D
author Albert E
author_facet Albert E
Burgos JS
Peiró S
Salas D
Vanaclocha H
Giménez E
Limón R
Alcaraz MJ
Sánchez-Payá J
Díez-Domingo J
Navarro D
author_role author
author2 Burgos JS
Peiró S
Salas D
Vanaclocha H
Giménez E
Limón R
Alcaraz MJ
Sánchez-Payá J
Díez-Domingo J
Navarro D
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Comirnaty (R) COVID-19 vaccine
Nursing home residents
SARS-CoV-2
SARS-CoV-2-S antibodies
topic Comirnaty (R) COVID-19 vaccine
Nursing home residents
SARS-CoV-2
SARS-CoV-2-S antibodies
description Objectives: The current study was aimed at examining SARS-CoV-2 immune responses following two doses of Comirnaty (R) COVID-19 vaccine among elderly people in nursing homes. Methods: A prospective cohort study in a representative sample from nursing homes in Valencia (n = 881; males: 271, females 610; median age, 86 years) recruited residents using a random one-stage cluster sampling approach. A lateral flow immunochromatography device (LFIC) (OnSite COVID-19 IgG/IgM Rapid Test; CTK BIOTECH, Poway, CA, USA) was used as the front-line test for detecting SARS-CoV-2-Spike (S)-specific antibodies in whole blood obtained using a fingerstick. Residents returning negative LFIC results underwent venipuncture and testing for presence of SARS-CoV-2-S-reactive antibodies and T cells using the Roche Elecsys (R) Anti-SARS-CoV-2 S (Roche Diagnostics, Pleasanton, CA, USA), the LIAISON (R) SARS-CoV-2 TrimericS IgG assay (Diasorin S.p.A, Saluggia, Italy) and by flow cytometry, respectively. Results: The SARS-CoV-2-S antibody detection rate in nursing home residents was 99.6% (283/284) and 98.3% (587/597) for SARS-CoV-2 recovered and naive residents, respectively, within a median of 99 days (range 17-125 days) after full vaccination. Three out of five residents lacking SARS-CoV-2-S antibodies had detectable S-reactive CD8(+) and/or CD4(+) T cells. In addition, 50/50 and 40/50 participants with detectable SARS-CoV-2 antibodies also had SARS-CoV-2-S reactive interferon-gamma-producing CD4(+) and CD8(+) T cells, respectively. Discussion: The Comirnaty (R) COVID-19 vaccine is highly immunogenic in nursing home residents. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/11347
url https://fisabio.portalinvestigacion.com/publicaciones/11347
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCI LTD
publisher.none.fl_str_mv ELSEVIER SCI LTD
dc.source.none.fl_str_mv CLINICAL MICROBIOLOGY AND INFECTION
ISSN: 1198743X
ISSNe: 14690691
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402999655235584
score 15,812429

Similares en LA Referencia